ClinicalTrials.gov
ClinicalTrials.gov Menu

Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01766986
Recruitment Status : Completed
First Posted : January 11, 2013
Last Update Posted : November 18, 2014
Sponsor:
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

Brief Summary:

Background: Owing to controversial staging and classification of adenocarcinoma of the oesophagogastric junction (AOG) before surgery, the choice of appropriate surgical approach remains problematic.

In a retrospective study, preoperative staging of AOG and the impact of preoperative misclassification on outcome were analysed. Methods: Data from patients with AOG were analysed from a prospectively collected database with regard to surgical treatment, preoperative and postoperative staging, and outcome.


Condition or disease
Esophageal Carcinoma

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 130 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Study Start Date : January 2008
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Overall survival [ Time Frame: 60 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
One-hundred and thirty patients with Siewert types I and II AOG who did not have neoadjuvant treatment were included in the study
Criteria

Inclusion Criteria:

  • One-hundred and thirty patients with Siewert types I and II AOG who did not have neoadjuvant treatment were included in the study

Exclusion Criteria:

  • AOG type III
  • no surgical resection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01766986


Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Investigators
Study Chair: Jakob R Izbicki, MD. University Hospital Hamburg-Eppendof, Hamburg, Germany

Responsible Party: Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier: NCT01766986     History of Changes
Other Study ID Numbers: AEGII-2012
First Posted: January 11, 2013    Key Record Dates
Last Update Posted: November 18, 2014
Last Verified: November 2014

Additional relevant MeSH terms:
Adenocarcinoma
Esophageal Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases